RenovoRx, Inc. announced on February 16, 2024, Angela Gill Nelms provided written notice to the company of her resignation as the company?s chief operating officer, effective March 1, 2024. Ms. Nelms resignation was for personal reasons and not as a result of any disagreement with the company on any matter relating to the company?s operations, policies or practices. On February 22, 2024, the company?s board of directors (the board), by unanimous written consent to action, appointed Leesa Gentry, the company?s current Senior Vice President of Clinical Operations, to the position of chief clinical officer of the company, effective March 1, 2024.

Ms. Gentry will be assuming any clinical and regulatory responsibilities that had previously been under Ms. Nelms?s purview, with the remainder of such responsibilities being assigned to other members of the company?s executive management team. Leesa Gentry, age 54, has served as its Senior Vice President of Clinical Operations since April 2023. From January 2019 to February 2023, Ms. Gentry served as Senior Vice President of Clinical Development and Operations for Evotec, GmbH.

Prior to her tenure at Evotec, Ms. Gentry spent 13 years, from November 2005 through December 2018, serving in positions of increasing responsibility for Otsuka Pharmaceutical Development and Commercialization (OPDC). These positions include Director, Associate Director, Sr. Manager of Clinical Management, and Program Manager. Prior to her tenure with Otsuka, Ms. Gentry held clinical management positions within contract research organizations from 1995 to 2005, including IQVIA, PPD, Omnicare CR, and IBRD-Rostrum Global.

Ms. Gentry holds an M.A. in psychology from the University of Mary Hardin-Baylor, as well as an M.S. in social gerontology and a B.A. in psychology from the University of Central Missouri.